版本:
中国

BRIEF-Eiger Biopharmaceuticals says completes enrollment of phase 2 liberty study of ubenimex

May 15 Eiger Biopharmaceuticals Inc:

* Eiger Biopharmaceuticals Inc says completes enrollment of phase 2 liberty study of ubenimex in pulmonary arterial hypertension Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐